These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 26824884)
41. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. Wallace M; Rauck RL; Moulin D; Thipphawong J; Khanna S; Tudor IC J Int Med Res; 2008; 36(2):343-52. PubMed ID: 18380946 [TBL] [Abstract][Full Text] [Related]
43. The role of OROS hydromorphone in the management of cancer pain. Gardner-Nix J; Mercadante S Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749 [TBL] [Abstract][Full Text] [Related]
44. The side effects of morphine and hydromorphone patient-controlled analgesia. Hong D; Flood P; Diaz G Anesth Analg; 2008 Oct; 107(4):1384-9. PubMed ID: 18806056 [TBL] [Abstract][Full Text] [Related]
45. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery. Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105 [TBL] [Abstract][Full Text] [Related]
46. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder. Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971 [TBL] [Abstract][Full Text] [Related]
47. Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-naïve patients with chronic pain. Arai T; Kashimoto Y; Ukyo Y; Tominaga Y; Imanaka K Curr Med Res Opin; 2015 Dec; 31(12):2207-18. PubMed ID: 26359327 [TBL] [Abstract][Full Text] [Related]
48. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
49. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days. Riff DS; Duckor S; Gottlieb I; Diamond E; Soulier S; Raymond G; Boesing SE Clin Ther; 2009 Oct; 31(10):2072-85. PubMed ID: 19922878 [TBL] [Abstract][Full Text] [Related]
50. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain. Taber L; Lynch SY; He E; Ripa SR Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111 [TBL] [Abstract][Full Text] [Related]
51. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406 [TBL] [Abstract][Full Text] [Related]
52. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Drover DR; Angst MS; Valle M; Ramaswamy B; Naidu S; Stanski DR; Verotta D Anesthesiology; 2002 Oct; 97(4):827-36. PubMed ID: 12357147 [TBL] [Abstract][Full Text] [Related]
53. A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain. Watanabe S; Pereira J; Tarumi Y; Hanson J; Bruera E J Palliat Med; 2008 May; 11(4):570-4. PubMed ID: 18454609 [TBL] [Abstract][Full Text] [Related]
54. Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain. A randomized controlled trial. Bruera E; Belzile M; Neumann CM; Ford I; Harsanyi Z; Darke A Support Care Cancer; 1999 Jul; 7(4):280-3. PubMed ID: 10423055 [TBL] [Abstract][Full Text] [Related]
55. Randomized clinical trial comparing a patient-driven titration protocol of intravenous hydromorphone with traditional physician-driven management of emergency department patients with acute severe pain. Chang AK; Bijur PE; Davitt M; Gallagher EJ Ann Emerg Med; 2009 Oct; 54(4):561-567.e2. PubMed ID: 19560838 [TBL] [Abstract][Full Text] [Related]
56. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet. Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273 [TBL] [Abstract][Full Text] [Related]
57. OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain. Carter NJ; Keating GM CNS Drugs; 2010 Apr; 24(4):337-61. PubMed ID: 20297858 [TBL] [Abstract][Full Text] [Related]
58. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Biondi D; Xiang J; Benson C; Etropolski M; Moskovitz B; Rauschkolb C Pain Physician; 2013; 16(3):E237-46. PubMed ID: 23703422 [TBL] [Abstract][Full Text] [Related]
59. An Analysis of Rescue Medication Utilization from a 3-Month, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Low Back Pain Treated with Single-Entity, Twice-Daily, Extended-Release Hydrocodone. Nalamachu S; deLeon-Casasola OA; Robinson CY; Galer BS; Gould E; Gammaitoni A Pain Med; 2015 Dec; 16(12):2338-43. PubMed ID: 26301791 [TBL] [Abstract][Full Text] [Related]
60. A negative correlation between hyperalgesia and analgesia in patients with chronic radicular pain: is hydromorphone therapy a double-edged sword? Suzan E; Eisenberg E; Treister R; Haddad M; Pud D Pain Physician; 2013 Jan; 16(1):65-76. PubMed ID: 23340535 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]